dr. wirth discusses the safety profile of lenvatinib as seen in the select trial
Published 10 years ago • 389 plays • Length 2:07Download video MP4
Download video MP3
Similar videos
-
0:57
dr. taylor discusses the toxicities and impact of lenvatinib in the select trial
-
3:37
dr. wirth discusses the results of the select trial in thyroid cancer
-
2:47
dr. wirth discusses the open-label extension of select
-
1:28
dr. wirth on the use of lenvatinib in hypertensive patients with thyroid cancer
-
8:28
lenvatinib in advanced dtc
-
6:47
lenvatinib: new kid on the block
-
6:53
sequencing in dtc: lenvatinib and sorafenib
-
1:05
dr. brose on unique elements of the lenvatinib trial
-
1:22
dr. cheng on phase iii findings of lenvatinib in hcc
-
1:17
dr. wirth discusses unmet needs in the treatment of thyroid cancer
-
2:20
dr. bruix discusses the updated findings of the resorce trial in hcc
-
3:56
lenvatinib: exploring dose reductions and interruptions
-
9:03
sequencing therapies for differentiated thyroid cancer
-
26:36
updates in the management of thyroid cancer virtual symposium presentation - lori wirth, md
-
2:47
dr. brose discusses lenvatinib and sorafenib in differentiated thyroid cancer
-
1:17
expectations for the treatment landscape of differentiated thyroid cancers in the future
-
15:19
phase iii select trial shows lenvatinib to be effective in resistant thyroid cancer
-
1:02:07
selpercatinib in ret-altered thyroid cancers with dr. lori wirth
-
1:46
dr wirth on the full fda approval of selpercatinib for advanced ret fusion thyroid cancer